ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report

Background: ALK fusion-positive NSCLC is driven by a range of fusion partners, most often EML4::ALK. The clinical impact, oncogenicity, and resistance mechanisms of rare, noncanonical ALK fusions remain underexplored. We describe two previously unreported ALK fusion partners in NSCLC and explore the...

Полное описание

Библиографические подробности

Главные авторы:	Charles Hsu, MD, Mohamed Yakoub, MD, PhD, Michael Offin, MD, Juliana Eng, MD, Alexander Drilon, MD, Soo-Ryum Yang, MD
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-03-01
Серии:	JTO Clinical and Research Reports
Предметы:	ALK fusion anaplastic lymphoma kinase NSCLC novel fusion partners next-generation sequencing
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2666364325001523
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!